Enfortumab Vedotin–related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature
Enfortumab vedotin (EV) is an antibody-drug conjugate approved for the treatment of refractory advanced urothelial cancer. Cutaneous toxicity is well described but has not been correlated with response. In this retrospective single-center study, data from patients treated with more than one dose of...
Main Authors: | Evangelia Vlachou, Andres Matoso, David McConkey, Yuezhou Jing, Burles Avner Johnson, 3rd, Noah M. Hahn, Jean Hoffman-Censits |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-03-01
|
Series: | European Urology Open Science |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666168323000022 |
Similar Items
-
Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
by: Shafique MA, et al.
Published: (2023-07-01) -
Desquamative extravasation reaction secondary to enfortumab vedotin
by: Akshay N. Pulavarty, MD, MPH, et al.
Published: (2024-04-01) -
Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
by: Bunpei Isoda, et al.
Published: (2023-06-01) -
Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
by: Brigida Anna Maiorano, et al.
Published: (2023-09-01) -
Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
by: Takashi Kawahara, et al.
Published: (2023-08-01)